Thursday, July 24, 2014 5:51:51 PM
Between 1928 and 1987 26 classes of antibiotics were discovered. The time between discovery and the identification of antibiotic resistance ranges from a low of 3 years to a high of 33 years. For example, Penicillin was discovered in 1928 and antibiotic resistance was identified in 1941, 13 years later.
Prior to the Cidin Class, of which Brilacidin is the first compound, the Lippeptides Class, to which Daptomycin belong,was the last class of antibiotics discovered in 1987 and resistance was identified in 2005.
Arguably, the biggest threat to public health is antibiotic-resistant infections. I believe Brilacidin will address this problem on two fronts: 1. A MOA that kills bacteria in minutes, before they can evolve, and 2. An effective single-dose therapy.
The antibiotic resistance problem is worsened by patient noncompliance and an effective single-dose bacterial therapy will not only alleviate this problem, but also confer a huge marketing advantage to CTIX.
The 3-legged stool of Dapto equivalency, MOA and single dose therapy will make B a one-of -a-kind game changer that will have a gargantuan effect on the treatment of antibiotic resistant infections and CTIX's share price.
Since resistance was eventually identified for the other 26 classes of antibiotics, I suppose one will someday be identified for Brilacidin. By the time that happens we should all be gazillionaires.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM